Marker Therapeutics Announces FDA Clearance of IND for MT-601, its Six-Antigen T Cell Therapy for the Treatment of Pancreatic Cancer

Marker Therapeutics, Inc. announced that the US FDA has cleared the company’s Investigational New Drug (IND) application for MT-601, a multi-tumor-associated antigen-specific T cell product targeting six antigens, for the treatment of patients with locally advanced unresectable or metastatic pancreatic cancer.